โ Home
โน๏ธ Info
๐งพ At a Glance ๐ Core Facts ๐๏ธ Products/Services โญ Ratings ๐งโ๐ผ Executives ๐ฌ My Comments๐ก Analytics
๐ Insights ๐ข Company Q&A (574) ๐ ๏ธ Industry Q&A (121) ๐ Competitors ๐ Price Low ๐ Price Swings โก SWOT ๐๏ธ PEST ๐ Porter's Five Forces โจ Score Positive โ ๏ธ Risk Assessment ๐งฉ Segmentation ๐ ถ Google Links๐ Ratios
๐ฐ Margins ๐ Financial Ratios ๐ฑ Growth ๐ Enterprise Value ๐ Key Metrics ๐ต Dividends๐ง Tools
โ Due Diligence๐ข Press Releases
| Date | Press release |
|---|---|
| 2026-03-24 10:00:00 | Pfizer Invites Public To View And Listen To Webcast Of May 5 Conference Call With Analysts New york--(business wire)--pfizer inc. (nyse: pfe) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. edt on tuesday, may 5, 2026. the purpose of the call is to provide an update on pfizerโs results, as reflected in the companyโs first quarter 2026 performance report, to be issued that morning. to view and listen to the webcast and view the performance report, visit our web site at www.pfizer.com/investors. inform. |
| 2026-03-23 06:45:00 | Pfizer And Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy In Phase 3 Valor Trial New york & lyon, france--(business wire)--pfizer inc. (nyse: pfe) and valneva se (nasdaq: valn; euronext paris: vla) today announced topline results from the phase 3 valor โvaccine against lyme for outdoor recreationistsโ clinical trial (nct05477524) of its investigational 6-valent ospa-based lyme disease vaccine candidate pf-07307405 (lb6v, formerly known as vla15) demonstrating: in the pre-specified analyses: efficacy of 73.2% from 28 days post-dose 4 (season 2) in reducing the rate of confir. |
| 2026-03-20 16:30:00 | Pfizer Recommends Shareholders Reject The Mini-tender Offer By Tutanota Llc New york--(business wire)--pfizer inc. (nyse: pfe) today announced that it has received notice of an unsolicited mini-tender offer by tutanota llc (โtutanotaโ) to purchase up to 1 million shares of pfizer common stock at a price of $32.00 per share in cash. the offer price of $32.00 per share is conditioned on, among other things, the closing price per share of pfizer common stock exceeding $32.00 per share on the last trading day before the offer expires. this means that unless this condition. |
| 2026-03-19 06:45:00 | Talzenna Plus Xtandi Significantly Improves Radiographic Progression-free Survival In Metastatic Prostate Cancer New york--(business wire)--pfizer inc. (nyse: pfe) today announced positive topline results from the phase 3 talapro-3 study of talzennaยฎ (talazoparib), an oral poly adp-ribose polymerase (parp) inhibitor, in combination with xtandiยฎ (enzalutamide), an androgen receptor pathway inhibitor (arpi), in people with homologous recombination repair (hrr) gene-mutated metastatic castration-sensitive prostate cancer (mcspc), also known as metastatic hormone-sensitive prostate cancer (mhspc). the study m. |
| 2026-03-17 06:45:00 | Pfizer Announces Positive Topline Phase 2 Results For Next-generation Cdk4 Inhibitor, Atirmociclib, In Second-line Metastatic Breast Cancer New york--(business wire)--pfizer inc. (nyse: pfe) today announced positive topline results from the randomized phase 2 fourlight-1 study evaluating atirmociclib in combination with fulvestrant, versus fulvestrant or everolimus plus exemestane, in people with hormone receptor (hr)-positive, human epidermal growth factor receptor 2-negative (her2-) advanced or metastatic breast cancer (mbc) who had received prior cyclin-dependent kinase (cdk) 4/6 inhibitor-based treatment. the study met its prim. |
| 2026-03-04 08:55:00 |
|
| 2026-02-27 10:00:00 |
|
| 2026-02-24 14:29:00 |
|
| 2026-02-24 07:45:00 |
|
| 2026-02-23 10:00:00 |
|
| 2026-02-23 08:00:00 |
|
| 2026-02-17 06:45:00 |
|
| 2026-02-09 08:50:00 |
|
| 2026-02-06 06:45:00 |
|
| 2026-02-05 19:09:00 |
|
๐ฐ Browse additional press releases for Pfizer!
Sign up for free or log in๐ Unlock our free guide: "The Checklist Value Investor โ A Smarter Way to Pick Stocks"